Shandong Lukang Pharmaceutical Gets China Marketing Approval for Antipsychotic API

MT Newswires Live

Aug 13

Shandong Lukang Pharmaceutical (SHA:600789) received marketing application approval from China's National Medical Products Administration for brexpiprazole as an active pharmaceutical ingredient, according to a Thursday filing with the Shanghai bourse.

The ingredient is an antipsychotic that helps balance dopamine and serotonin, according to the filing.

Lukang has so far invested nearly 4.8 million yuan in research and development of the drug, it said.

Shares rose 2% during afternoon trading on Thursday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2659846139"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2659846139\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2659846139?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-13 14:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2659846139","market":"fut","top_or_hot":-1,"title":"Shandong Lukang Pharmaceutical Gets China Marketing Approval for Antipsychotic API","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/600789\">Shandong Lukang</a> Pharmaceutical (SHA:600789) received marketing application approval from China's National Medical Products Administration for brexpiprazole as an active pharmaceutical ingredient, according to a Thursday filing with the Shanghai bourse.</p><p>The ingredient is an antipsychotic that helps balance dopamine and serotonin, according to the filing.</p><p>Lukang has so far invested nearly 4.8 million yuan in research and development of the drug, it said.</p><p>Shares rose 2% during afternoon trading on Thursday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shandong Lukang Pharmaceutical Gets China Marketing Approval for Antipsychotic API</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShandong Lukang Pharmaceutical Gets China Marketing Approval for Antipsychotic API\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-13 14:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/600789\">Shandong Lukang</a> Pharmaceutical (SHA:600789) received marketing application approval from China's National Medical Products Administration for brexpiprazole as an active pharmaceutical ingredient, according to a Thursday filing with the Shanghai bourse.</p><p>The ingredient is an antipsychotic that helps balance dopamine and serotonin, according to the filing.</p><p>Lukang has so far invested nearly 4.8 million yuan in research and development of the drug, it said.</p><p>Shares rose 2% during afternoon trading on Thursday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK6100","symbol_name":"保健护理服务","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2659846139","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2659846139","pubTimestamp":1786603311,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shandong Lukang Pharmaceutical  received marketing application approval from China's National Medical Products Administration for brexpiprazole as an active pharmaceutical ingredient, according to a Thursday filing with the Shanghai bourse.The ingredient is an antipsychotic that helps balance dopamine and serotonin, according to the filing.Lukang has so far invested nearly 4.8 million yuan in research and development of the drug, it said.Shares rose 2% during afternoon trading on Thursday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600789":"鲁抗医药","BK6100":"保健护理服务","BK0188":"融资融券","OTX.SI":"迈怡汇有限公司","BK0168":"禽流感","BK6520":"工商业服务概念","BK0046":"生物疫苗","BK0239":"医药制造"},"translate_title":"山东鲁抗制药抗精神病原料药获得中国上市许可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600789":0.9,"OTX.SI":1.5},"content_text":"Shandong Lukang Pharmaceutical (SHA:600789) received marketing application approval from China's National Medical Products Administration for brexpiprazole as an active pharmaceutical ingredient, according to a Thursday filing with the Shanghai bourse.The ingredient is an antipsychotic that helps balance dopamine and serotonin, according to the filing.Lukang has so far invested nearly 4.8 million yuan in research and development of the drug, it said.Shares rose 2% during afternoon trading on Thursday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}